

PEOPLE

J. Claude Bennett, currently president of the University of Alabama at Birmingham, will assume the office of president and CEO of BioCryst (Birmingham, AL). Dr. Bennett will also join BioCryst's board of directors, increasing the board to ten members.

Michael F. Bigham and **Jack S. Remington** have been elected to IntraBiotics' (Sunnyvale, CA) board of directors. Mr. Bigham is president and CEO of Coulter Pharmaceuticals, and Dr. Remington is chairman, department of immunology and infectious diseases at the Research Institute of the Palo Alto Medical Foundation.

Isis Pharmaceuticals (Carlsbad, CA) has announced that **Stephen K. Carter**, senior vice president of R&D with Boehringer Ingelheim Pharmaceuticals, has joined the Isis board of directors. Dr. Carter replaces **Christoph Hohbach**, head of the corporate division, R&D, Boehringer Ingelheim GmbH.

The Massachusetts Biotechnology Council (MBC, Cambridge, MA) has announced the appointment of **Carol A. Fassino** to the position of director, contracts and services, of the MBC Purchasing Consortium. Prior to joining the MBC, Ms. Fassino served as purchasing manager for Alpha-Beta.

Diacrin (Charlestown, MA) has promoted **Mark Fitzpatrick** from director of finance and administration to vice president of finance and administration and CFO.

Barrie S. Haigh, **Paul Knott**, and **Vaughn D. Bryson** have been elected to Quintiles Transnational's (Research Triangle Park, NC) board of directors. Two current board members, Quintiles' executive vice president **Sara Creagh** and Quintiles America president **Bill Sollecito**, are retiring. Haigh is vice chairman of Quintiles; Knott is senior vice president of international strategic development for Quintiles; Bryson is vice chairman of Vector Securities.

Collagen Corp. (Palo Alto, CA) has announced the appointments of four key individuals: **Carol F.H. Harner** as vice president, scientific affairs; **Charlene D. Andros** as

general counsel and assistant secretary; **Reinhard Koenig** as vice president, medical affairs; and **Jane A. Moffitt** as vice president, regulatory affairs, worldwide. Prior to joining Collagen Corp., Harner was principal scientist/senior program manager with Chiron Ophthalmics and senior scientist at CooperVision Surgical. Andros joined Collagen Corp. as its general counsel and assistant secretary in February 1996, from the law firm of Lillick & Charles in San Francisco. Dr. Koenig joined Collagen Corp. in October 1996 as vice president, medical affairs, from Genentech, where he was director of medical information and drug experience. Moffitt joins Collagen Corp. from Amsco International in Pittsburgh, where she held the position of vice president regulatory affairs/quality assurance.

Catherine Harrington has joined the health-care consulting firm, The Lewin Group (Washington, DC), as vice president in the medical technology group. Dr. Harrington was previously vice president for clinical program development at ValueRx, and is a member of the United States Pharmacopeial Convention Advisory Panel on Drug Utilization Review.

Parexel (Boston, MA) has named **James Karis** as COO and president of worldwide research operations. Previously, Mr. Karis was COO of Pharmaco International. Parexel has also named **Victoria M. Kusiak** as vice president of worldwide medical affairs services. Dr. Kusiak was most recently employed by Johnson and Johnson as vice president, clinical research, of its R.W. Johnson Pharmaceutical Research Institute.

Thomas King, COO of Anesta (Salt Lake City, UT), has been appointed as president of the company. The former president, **William Moeller**, will continue as CEO.

Stephen J. Kondor has been appointed as vice president of marketing and sales of Biometric Imaging (Mountain View, CA). He recently served as commercial director of the hematology business unit for Abbott Diagnostic Division.

Phytera, Inc. (Worcester, MA) has announced that it has appointed **James B. McAlpine**, formerly senior project manager, natural product screening at Abbott Laboratories, as director of natural product chemistry. Also, **Soren V.S. Nielsen**, formerly of the Danish Institute of Plant and Soil Science, has been named research director of the company's recently established subsidiary in Denmark, Phytera A/S.

GeneMedicine (The Woodlands, TX) has announced the appointments of **Jeffrey Nordstrom** to director of gene expression systems, **Ross Durland** to director of plasmid analytics, and **John Welp** to director of integrated manufacture. These positions have been created to assist in the company's expanded efforts in the research, clinical development, and production of pharmaceutically acceptable, nonviral gene medicines. All three are currently senior staff members at GeneMedicine.

Fred Ruegsegger is the new chief financial officer of Arris Pharmaceuticals (South San Francisco, CA), replacing **Dan Petree**, who has been promoted to executive vice president. Previously, Ruesegger was president and chief executive officer of EyeSys Technologies (Houston, TX).

Alpha Therapeutic Corp. (Los Angeles, CA) has announced the promotion of **Carolyn Siegal** to vice president, business development. Ms. Siegal had previously been director, business development and planning, at Alpha.

Randy H. Thurman and **Wendell Wierenga** have been appointed to the board of directors of ONYX Pharmaceuticals (Richmond, CA). Mr. Thurman most recently served as chairman and CEO of Corning Life Sciences. Dr. Wierenga is senior vice president for research at Parke-Davis Pharmaceutical Research, a division of Warner-Lambert.

Third Wave Technologies (Madison, WI) has named its new chief operating officer and executive vice president. He is **Michael J. Treble**, most recently chairman of the board of Genetic Models, Inc. Mr. Treble will also join the board of directors. The company has also announced three senior appointments: **Bruce P. Neri**, previously of Becton Dickinson, as vice president, R&D; **Rocky E. Ganske**, also formerly with Becton Dickinson, as vice president, operations; and **Mary E. Holland**, previously with Oncogenetics and Genetrix, as director, business development.

Ronald Tuttle is retiring as chief scientific officer of Houghton Pharmaceuticals (San Diego, CA) but he will remain on the company's board of directors and scientific advisory board.

Oncogene Science (Uniondale, NY) has promoted **Robert Van Nostrand** from vice president of finance administration, treasurer, and company secretary to vice president and chief financial officer.



Carol F.H. Harner Reinhard Koenig Charlene D. Andros